14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CFRX ranks #16422 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

ContraFect Corporation Stock Forecast NASDAQ:CFRX

$2.36 (-3.28%)

Volume: 97k

Closed: Jan 21, 2022

Hollow Logo Score: -4.327

ContraFect Corporation Stock Forecast

$2.36 (-3.28%)

Volume: 97k

Closed: Jan 21, 2022

Score Hollow Logo -4.327

ContraFect Corporation Company Profile

28 Wells Avenue

Yonkers NY 10701



Industry: Biotechnology

Sector: Healthcare

ContraFect Corporation


ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. The company was founded in 2008 and is headquartered in Yonkers, New York.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE